Biopharma | April 16, 2026
Aurobindo’s TheraNym to invest up to $175 million in expanded biologics deal with MSD
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
TheraNym will set up a greenfield large-scale mammalian drug substance manufacturing facility
Samsung Biologics will continue supplying products previously manufactured at the site to GSK
Move aligns global biologics identity under the Biocon Biologics brand
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
The CDMO Leadership Awards spotlight top-performing development and manufacturing service providers
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
Capital infusion to accelerate Earendil’s R&D platform
The planned facility, to be built at Samsung’s Bio Campus II, is set to become a launchpad for up to 30 emerging biotech firms
Marks significant milestone for breakthrough biologic to treat rare blood cancers
ShunzymeX leverages a proprietary protease to streamline purification
Subscribe To Our Newsletter & Stay Updated
